Mouse Anti-TARDBP Monoclonal Antibody (CBP2838)

Product Overview

Description

Transactivation response (TAR) was first isolated as a transcriptional inactivator binding to the TAR DNA element of the HIV-1 virus. Neumann et al. (2006) found that a hyperphosphorylated, ubiquitinated, and cleaved form of TARDBP, known as pathologic TDP-43, is the major component of the tau-negative and ubiquitin-positive inclusions that characterize amyotrophic lateral sclerosis (ALS) and the most common pathological subtype of frontotemporal lobar degeneration (FTLD-U).

Expression Host

Mammalian cells

Immunogen

Fusion protein

Species Reactivity

Human; Rat; Mouse

Clonality

Monoclonal

Host Species

Mouse

Isotype

IgG1

Clone Number

CBP2838

Applications

FC; IHC; WB; ELISA

Application Notes

IHC : 1:20-1:200; WB : 1:500-1:1000

Research Areas

Neural Cell

Conjugation

Unconjugated

Product Properties

Form

Liquid

Formulation

PBS, 0.1% sodium azide and 50% glycerol pH 7.3.

Preservatives

Yes

Concentration

1000 μg/ml

Purification

Antigen affinity purification

Purity

>95%, as determined by SDS-PAGE

Shipping

The product is shipped at 4°C. Upon receipt, store it immediately at the temperature recommended below.

Storage

Store at -20°C. Stable for one year after shipment.

Research Use Only

For research use only, not for diagnostic or therapeutic use.

Target

TDP43

Official Name

TDP-43

Full Name

TAR DNA binding protein

Alternative Names

ALS10; TAR DNA binding protein; TAR DNA binding protein 43; TARDBP; TDP 43; TDP43

Gene ID

23435(Human); 230908(Mouse); 298648(Rat)

Uniprot ID

Q13148(Human); Q921F2(Mouse)

References

1. Tawara, N., Yamashita, S., Kawakami, K., Kurashige, T., Zhang, Z., Tasaki, M.,... & Matsuo, Y. (2018). Muscle-dominant wild-type TDP-43 expression induces myopathological changes featuring tubular aggregates and TDP-43-positive inclusions. Experimental Neurology, 309, 169-180. 2. Nana, A. L., Sidhu, M., Gaus, S. E., Hwang, J. H. L., Li, L., Park, Y.,... & Toller, G. (2019). Neurons selectively targeted in frontotemporal dementia reveal early stage TDP-43 pathobiology. Acta neuropathologica, 137(1), 27-46.

Publications